Order:
  1.  27
    Correction to: Synthetic Biology and the Translational Imperative.Raheleh Heidari Feidt, Marcello Ienca, Bernice Simone Elger & Marc Folcher - 2019 - Science and Engineering Ethics 25 (1):53-53.
    The author group of above-mentioned review paper was incorrectly published in the online article.
    Direct download (2 more)  
     
    Export citation  
     
    Bookmark  
  2.  33
    Synthetic Biology and the Translational Imperative.Raheleh Heidari Feidt, Marcello Ienca, Bernice Simone Elger & Marc Folcher - 2019 - Science and Engineering Ethics 25 (1):33-52.
    Advances at the interface between the biological sciences and engineering are giving rise to emerging research fields such as synthetic biology. Harnessing the potential of synthetic biology requires timely and adequate translation into clinical practice. However, the translational research enterprise is currently facing fundamental obstacles that slow down the transition of scientific discoveries from the laboratory to the patient bedside. These obstacles including scarce financial resources and deficiency of organizational and logistic settings are widely discussed as primary impediments to translational (...)
    Direct download (2 more)  
     
    Export citation  
     
    Bookmark  
  3.  18
    Correction to: Synthetic Biology and the Translational Imperative.Marc Folcher, Bernice Simone Elger, Marcello Ienca & Raheleh Heidari Feidt - 2019 - Science and Engineering Ethics 25 (1):53-53.
    The author group of above-mentioned review paper was incorrectly published in the online article.
    Direct download (2 more)  
     
    Export citation  
     
    Bookmark  
  4.  27
    Synthetic Biology and the Translational Imperative. [REVIEW]Marc Folcher, Bernice Simone Elger, Marcello Ienca & Raheleh Heidari Feidt - 2019 - Science and Engineering Ethics 25 (1):33-52.
    Advances at the interface between the biological sciences and engineering are giving rise to emerging research fields such as synthetic biology. Harnessing the potential of synthetic biology requires timely and adequate translation into clinical practice. However, the translational research enterprise is currently facing fundamental obstacles that slow down the transition of scientific discoveries from the laboratory to the patient bedside. These obstacles including scarce financial resources and deficiency of organizational and logistic settings are widely discussed as primary impediments to translational (...)
    Direct download (2 more)  
     
    Export citation  
     
    Bookmark